SAREPTA THERAPEUTICS Q3 2017 EARNINGS CONFERENCE CALL
FORWARD-LOOKING STATEMENTS

In order to provide Sarepta's investors with an understanding of its current results and future prospects, forward-looking statements will be made during this conference call. Any statements made by Sarepta that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "may," "intends," "prepares," "looks," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements by management relating to Sarepta's future operations, financial performance and projections, business plans, priorities and research and development programs including: the timing of Sarepta's 10-Q filing for Q3 2017; Sarepta's mission to profoundly improve the life of children suffering from DMD and Sarepta having the technology, the pipeline, the resources, the talent and the passion to fulfill that mission; the update to Sarepta's full-year revenue guidance to $150 million to $155 million; Sarepta being well positioned going into 2018, its ability to continue the successful launch for EXONDYS 51 and its expectation for a strong finish to the year; Sarepta's fine performance being driven by the positive impact of EXONDYS 51 and its team's tenacious execution; the potential success of EXONDYS 51's launch compared to other launches in history; the 4053-101 results and Sarepta's goal to bring golodirsen to the DMD community; Sarepta's plans, as part of its corporate strategy, to work doggedly to ensure that eligible patients are able to gain access and benefit from its DMD therapies and to rapidly and diligently advance its pipeline; the potential of PPMO and Sarepta's strategy to advance multiple additional PPMO candidates; Sarepta's collaborations with third parties, the potential of the collaborations and plans and timelines to enter the clinic and dose patients; Sarepta's expectation to accelerate its pipeline and to pursue new innovative approaches to treat DMD and other rare neuromuscular diseases under Dr. Basi's leadership; Sarepta's expectations regarding port use by patients, education programs on genetic testing, sale trends continuing and discussions with payers on prescriptions, START Forms, patients starting on therapy and reimbursement landscape for EXONDYS 51; Sarepta's plans to continue to expand globally and build global infrastructure; Sarepta's plan to expand its MAP and the revenue expectation associated with this program; and Sarepta's plans for the coming months, including having 7 programs in the clinic by year-end 2017, the micro-dystrophin and the GALGT2 collaborations entering the clinic this year, dosing the first patient in the PPMO program by year-end 2017, completing enrollment in the ESSENCE study by year-end 2017 or earlier in the first quarter of 2018, meeting with the FDA in the first quarter of 2018 to discuss the golodirsen program, Summit Therapeutics announcing data from their Phase 2 proof-of-concept clinical trial in the first quarter of 2018, and completion of the review of our application by the CHMP in the first half of 2018.

These forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta's control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: we may not be able to meet expectations with respect to EXONDYS 51 sales or attain the net revenues we anticipate for 2017, profitability or positive cash-flow from operations; we may not be able to comply with all FDA post-approval commitments and requirements with respect to EXONDYS 51 in a timely manner or at all; we may not be able to obtain regulatory approval for eteplirsen in jurisdictions outside of the U.S. including from the European Medicines Agency; our data for golodirsen (SRP-4053) may not be sufficient for a filing for or obtaining regulatory approval; we may not be able to complete clinical trials required by the FDA or other regulatory authorities for approval of golodirsen (SRP-4053) or any of our other product candidates; the results of our ongoing research and development efforts, including those with strategic partners, and clinical trials for golodirsen (SRP-4053) and our other product candidates may not be positive or consistent with prior results or demonstrate a safe treatment benefit which could negatively impact our business; we may not be able to execute on our business plans, including meeting our expected or planned regulatory milestones and timelines, clinical development plans, and bringing our product candidates to market, for various reasons including possible limitations of Company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, and regulatory, court or agency decisions, such as decisions by the European CHMP on eteplirsen or the United States Patent and Trademark Office with respect to patents that cover our product candidates; we may not be able to establish and successfully conduct a MAP in one or more countries, and even if such program(s) are successfully conducted, we may not achieve any significant revenues; and those risks identified under the heading "Risk Factors" in Sarepta's most recent Annual Report on Form 10-K for the year ended December 31, 2016 or most recently filed Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review.

Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. You should not place undue reliance on forward-looking statements. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except to the extent required by applicable law or SEC rules.